Uncategorized
Treat-and-extend dosing reduces treatment burden in TREX-AMD trial
CHICAGO — Treatment burden was significantly reduced with treat-and-extend dosing vs. monthly dosing of ranibizumab through 2 years in the TREX-AMD study, an investigator reported here. Charles C. Wykoff , MD, PhD, presented the study results at Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting. The trial was funded by a grant from Genentech.